KR101947588B1 - 인간 배아줄기세포 유래된 혈액모세포로부터 자연 살해 세포 및 수지상 세포를 생성하는 방법 - Google Patents

인간 배아줄기세포 유래된 혈액모세포로부터 자연 살해 세포 및 수지상 세포를 생성하는 방법 Download PDF

Info

Publication number
KR101947588B1
KR101947588B1 KR1020127017370A KR20127017370A KR101947588B1 KR 101947588 B1 KR101947588 B1 KR 101947588B1 KR 1020127017370 A KR1020127017370 A KR 1020127017370A KR 20127017370 A KR20127017370 A KR 20127017370A KR 101947588 B1 KR101947588 B1 KR 101947588B1
Authority
KR
South Korea
Prior art keywords
cells
cell
delete delete
various embodiments
stem cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020127017370A
Other languages
English (en)
Korean (ko)
Other versions
KR20120112511A (ko
Inventor
에린 킴브렐
쉬-지앙 루
Original Assignee
스템 셀 앤드 리제너러티브 메디신 인터내셔날, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스템 셀 앤드 리제너러티브 메디신 인터내셔날, 인크. filed Critical 스템 셀 앤드 리제너러티브 메디신 인터내셔날, 인크.
Publication of KR20120112511A publication Critical patent/KR20120112511A/ko
Application granted granted Critical
Publication of KR101947588B1 publication Critical patent/KR101947588B1/ko
Assigned to 아스텔라스 인스티튜트 포 리제너러티브 메디슨 reassignment 아스텔라스 인스티튜트 포 리제너러티브 메디슨 권리의 전부이전등록 Assignors: 스템 셀 앤드 리제너러티브 메디신 인터내셔날, 인크.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/165—Vascular endothelial growth factor [VEGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2303—Interleukin-3 (IL-3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
KR1020127017370A 2009-12-04 2010-12-01 인간 배아줄기세포 유래된 혈액모세포로부터 자연 살해 세포 및 수지상 세포를 생성하는 방법 Active KR101947588B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26666109P 2009-12-04 2009-12-04
US61/266,661 2009-12-04
PCT/US2010/058593 WO2011068896A1 (en) 2009-12-04 2010-12-01 Method of generating natural killer cells and dendritic cells from human embryonic stem cell-derived hemangioblasts

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020197003655A Division KR20190016602A (ko) 2009-12-04 2010-12-01 인간 배아줄기세포 유래된 혈액모세포로부터 자연 살해 세포 및 수지상 세포를 생성하는 방법

Publications (2)

Publication Number Publication Date
KR20120112511A KR20120112511A (ko) 2012-10-11
KR101947588B1 true KR101947588B1 (ko) 2019-02-14

Family

ID=44115272

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020127017370A Active KR101947588B1 (ko) 2009-12-04 2010-12-01 인간 배아줄기세포 유래된 혈액모세포로부터 자연 살해 세포 및 수지상 세포를 생성하는 방법
KR1020207018660A Ceased KR20200083645A (ko) 2009-12-04 2010-12-01 인간 배아줄기세포 유래된 혈액모세포로부터 자연 살해 세포 및 수지상 세포를 생성하는 방법
KR1020197003655A Ceased KR20190016602A (ko) 2009-12-04 2010-12-01 인간 배아줄기세포 유래된 혈액모세포로부터 자연 살해 세포 및 수지상 세포를 생성하는 방법
KR1020257009314A Pending KR20250048382A (ko) 2009-12-04 2010-12-01 인간 배아줄기세포 유래된 혈액모세포로부터 자연 살해 세포 및 수지상 세포를 생성하는 방법
KR1020217030824A Ceased KR20210120136A (ko) 2009-12-04 2010-12-01 인간 배아줄기세포 유래된 혈액모세포로부터 자연 살해 세포 및 수지상 세포를 생성하는 방법

Family Applications After (4)

Application Number Title Priority Date Filing Date
KR1020207018660A Ceased KR20200083645A (ko) 2009-12-04 2010-12-01 인간 배아줄기세포 유래된 혈액모세포로부터 자연 살해 세포 및 수지상 세포를 생성하는 방법
KR1020197003655A Ceased KR20190016602A (ko) 2009-12-04 2010-12-01 인간 배아줄기세포 유래된 혈액모세포로부터 자연 살해 세포 및 수지상 세포를 생성하는 방법
KR1020257009314A Pending KR20250048382A (ko) 2009-12-04 2010-12-01 인간 배아줄기세포 유래된 혈액모세포로부터 자연 살해 세포 및 수지상 세포를 생성하는 방법
KR1020217030824A Ceased KR20210120136A (ko) 2009-12-04 2010-12-01 인간 배아줄기세포 유래된 혈액모세포로부터 자연 살해 세포 및 수지상 세포를 생성하는 방법

Country Status (11)

Country Link
US (3) US8822218B2 (enExample)
EP (1) EP2507365A4 (enExample)
JP (5) JP6013187B2 (enExample)
KR (5) KR101947588B1 (enExample)
CN (1) CN102822332A (enExample)
AU (1) AU2010326027A1 (enExample)
BR (1) BR112012014104A2 (enExample)
CA (3) CA3080368A1 (enExample)
IN (1) IN2012DN05053A (enExample)
RU (1) RU2012127811A (enExample)
WO (1) WO2011068896A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102651433B1 (ko) 2006-04-14 2024-03-25 아스텔라스 인스티튜트 포 리제너러티브 메디슨 혈관 콜로니 형성 세포
BR112012014104A2 (pt) 2009-12-04 2016-07-05 Stem Cell & Regenerative Medicine International Inc método de geração de células destrutoras naturais e células dendríticas de hemangioblastos embrionários humanos derivados de células-tronco
US8961956B2 (en) 2011-11-30 2015-02-24 Ocata Therapeutics, Inc. Mesenchymal stromal cells and uses related thereto
RS57886B1 (sr) 2011-11-30 2019-01-31 Astellas Inst For Regenerative Medicine Mezenhimalne stromalne ćelije i primene vezane za njih
US9260696B2 (en) 2012-04-24 2016-02-16 Dan S. Kaufman Method for developing natural killer cells from stem cells
CA2876499C (en) 2012-07-12 2021-10-26 Imstem Biotechnology, Inc. Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
CN114558032B (zh) 2012-12-21 2025-07-29 安斯泰来再生医药协会 由多能干细胞制备血小板的方法及其组合物
CN106103701B (zh) * 2014-01-03 2020-04-24 中央研究院 改造的自然杀手细胞及其组成与用途
CN105219710B (zh) * 2014-06-05 2020-01-10 上海厚超生物科技有限公司 一种高杀伤活性的免疫细胞群的培养方法
DE102014014993B4 (de) * 2014-10-09 2017-02-02 Helga Schmetzer Verwendung von immunmodulatorisch wirksamen Kits zur immuntherapeutischen Behandlung von Patienten mit myeloischen Leukämien
CN104711225B (zh) * 2015-04-09 2018-05-22 奥思达干细胞有限公司 Nk细胞的体外制备方法
SG10201913250SA (en) 2015-08-18 2020-03-30 Astellas Inst For Regenerative Medicine Clinical formulations
CN105219717A (zh) * 2015-10-20 2016-01-06 上海隆耀生物科技有限公司 一种一型极化树突状细胞及其诱导方法和应用
CN105219719A (zh) * 2015-10-20 2016-01-06 上海隆耀生物科技有限公司 一种用于激活卵巢癌特异性免疫反应的试剂盒
CN105219722A (zh) * 2015-10-20 2016-01-06 上海隆耀生物科技有限公司 一种用于激活肾癌特异性免疫反应的试剂盒
CN105219723A (zh) * 2015-10-20 2016-01-06 上海隆耀生物科技有限公司 一种用于激活胃癌特异性免疫反应的试剂盒
CN105219725A (zh) * 2015-10-20 2016-01-06 上海隆耀生物科技有限公司 一种用于激活肉瘤特异性免疫反应的试剂盒
CN105219728A (zh) * 2015-10-20 2016-01-06 上海隆耀生物科技有限公司 一种用于激活乳腺癌特异性免疫反应的试剂盒
CN105219727A (zh) * 2015-10-20 2016-01-06 上海隆耀生物科技有限公司 一种用于激活结直肠癌特异性免疫反应的试剂盒
CN105219718A (zh) * 2015-10-20 2016-01-06 上海隆耀生物科技有限公司 一种用于激活前列腺癌特异性免疫反应的试剂盒
CN105219716A (zh) * 2015-10-20 2016-01-06 上海隆耀生物科技有限公司 一种用于激活头颈部癌特异性免疫反应的试剂盒
CN105219726A (zh) * 2015-10-20 2016-01-06 上海隆耀生物科技有限公司 一种高效制备一型极化树突状细胞的方法及其应用
KR102167548B1 (ko) * 2017-09-21 2020-10-19 한국생명공학연구원 자연살해세포의 제조방법 및 그의 용도
GB201810486D0 (en) 2018-06-26 2018-08-08 Imperial Innovations Ltd Natural killer cells
CN113166726A (zh) 2019-07-08 2021-07-23 南克维斯特公司 单核细胞源性nk细胞
US11453862B2 (en) 2019-07-08 2022-09-27 Immunitybio, Inc. Mononuclear cell derived NK cells
US11547726B2 (en) * 2020-03-26 2023-01-10 Honed Life Sciences, Llc Enhancement of production of NK cells from stem cells
US11459372B2 (en) 2020-11-30 2022-10-04 Crispr Therapeutics Ag Gene-edited natural killer cells
KR102292843B1 (ko) * 2020-12-29 2021-08-25 주식회사 온코인사이트 역분화줄기세포(iPSC) 유래 자연 살해 세포 및 이의 용도
US11473060B2 (en) 2020-12-30 2022-10-18 Crispr Therapeutics Ag Compositions and methods for differentiating stem cells into NK cells
CN115247149B (zh) * 2022-08-22 2023-06-16 华域生物科技(天津)有限公司 适用于nk细胞的培养基组合物及培养方法
CN120659871A (zh) * 2022-09-02 2025-09-16 帝国理工学院创新有限公司 自然杀伤细胞
KR20250127134A (ko) 2022-12-29 2025-08-26 아스텔라스세이야쿠 가부시키가이샤 조작된 자연 살상 세포 및 관련 방법
WO2025212519A1 (en) 2024-04-01 2025-10-09 Moonlight Bio, Inc. Dll3 binding proteins and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070141703A1 (en) * 2003-11-19 2007-06-21 Stanley Edouard G Methods for producing blood products from pluripotent cells in cell culture

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0765398B1 (en) * 1994-06-15 2003-06-04 Systemix, Inc. Population of cells enriched for myeloid and/or lymphoid progenitors and methods of making and using
JP2002515756A (ja) * 1997-01-31 2002-05-28 ヘモソル インク． 選択されたリンパ球の生産方法
WO1998053048A1 (en) * 1997-05-21 1998-11-26 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods and compositions for making dendritic cells from expanded populations of monocytes and for activating t cells
JP2001525176A (ja) * 1997-12-04 2001-12-11 デューク・ユニバーシティー Ｃｄ７＋ｃｄ３４−ｌｉｎ−造血細胞を単離し、使用する方法
FR2801056B1 (fr) * 1999-11-12 2003-03-28 Commissariat Energie Atomique Proteine presente a la surface des cellules souches hematopoietiques de la lignee lymphoide et des cellules nk, et ses applications
KR20020083634A (ko) * 2001-04-27 2002-11-04 크레아젠 주식회사 수지상 세포를 포함하는 자가면역 질환의 치료용 약제학적조성물 및 이를 이용한 치료방법
US20050042751A1 (en) * 2001-10-31 2005-02-24 Michel Goldman Generation and use of new types of dendritic cells
WO2004050855A2 (en) * 2002-12-04 2004-06-17 Baylor Research Institute Rapid one-step method for generation of antigen loaded dendritic cell vaccine from precursors
US20050032210A1 (en) * 2003-03-18 2005-02-10 Kirin Beer Kabushiki Kaisha Method of preparing immuno-regulatory dendritic cells and the use thereof
EP2263698A1 (en) * 2003-04-01 2010-12-22 United States of America Dempartment of Veteran's Affairs Stem-cell, precursor cell, or target cell-based treatment of multi-organ failure and renal dysfunction
WO2005085426A1 (ja) * 2004-03-04 2005-09-15 Tanabe Seiyaku Co., Ltd. 無フィ−ダ−分化用培地及び霊長類動物胚性幹細胞からの無フィ−ダ−分化方法
CA2571844A1 (en) * 2004-06-24 2006-01-05 Dnavec Research Inc. Anticancer agent containing minus-strand rna virus
US20080145931A1 (en) * 2004-10-07 2008-06-19 Argos Therapeutics, Inc. Mature Dendritic Cell Compositions and Methods of Culturing Same
US20080166751A1 (en) * 2005-02-23 2008-07-10 Takayuki Asahara Method of Analyzing Dynamics in the Differentiation of Vascular Endothelial Progenitor Cells
KR20150032915A (ko) * 2005-04-08 2015-03-30 아르고스 쎄라퓨틱스 인코포레이티드 수지상 세포 조성물 및 방법
GB2440494B (en) * 2005-06-01 2010-07-28 Wisconsin Alumni Res Found Method of forming dendritic from embryonic stem cells
DK1941027T3 (da) * 2005-09-28 2014-10-13 Ipd Therapeutics B V Fremgangsmåder og midler til stamcelleforøgelse og efterfølgende generering og ekspansion af progenitorceller samt produktion af effektorceller som kliniske terapeutika
KR102651433B1 (ko) * 2006-04-14 2024-03-25 아스텔라스 인스티튜트 포 리제너러티브 메디슨 혈관 콜로니 형성 세포
WO2008038279A2 (en) * 2006-09-25 2008-04-03 Kfir Nissan Force transducer and method
EP2088190A4 (en) 2006-11-09 2011-01-05 Japan Government METHOD FOR THE CULTURE AND PASSING OF AN EMBRYONAL PRIMATIVE STEM CELL AND METHOD FOR INDUCING THE DIFFERENTIATION OF THE EMBRYONAL STEM CELL
DE102006054041B3 (de) * 2006-11-16 2008-05-08 Pierburg Gmbh Regelvorrichtung für eine Verbrennungskraftmaschine
CA2700617C (en) * 2007-09-28 2018-11-06 Celgene Cellular Therapeutics Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
WO2009120891A2 (en) * 2008-03-27 2009-10-01 Geron Corporation Differentiation of primate pluripotent stem cells to hematopoietic lineage cells
KR20210003301A (ko) * 2008-05-06 2021-01-11 아스텔라스 인스티튜트 포 리제너러티브 메디슨 다능성 줄기세포로부터 유도된 탈핵 적혈구계 세포를 생산하는 방법
EP2712921B1 (en) 2008-05-06 2018-07-11 Astellas Institute for Regenerative Medicine Hemangio colony forming cells and non-engrafting hemangio cells
CN102388130B (zh) * 2009-02-27 2014-08-27 细胞动力国际有限公司 多能细胞的分化
BR112012014104A2 (pt) 2009-12-04 2016-07-05 Stem Cell & Regenerative Medicine International Inc método de geração de células destrutoras naturais e células dendríticas de hemangioblastos embrionários humanos derivados de células-tronco

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070141703A1 (en) * 2003-11-19 2007-06-21 Stanley Edouard G Methods for producing blood products from pluripotent cells in cell culture

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Blood. 112(9):3601-14 (2008.11.01.)*

Also Published As

Publication number Publication date
KR20190016602A (ko) 2019-02-18
US20150140657A1 (en) 2015-05-21
KR20200083645A (ko) 2020-07-08
IN2012DN05053A (enExample) 2015-10-09
CA3080368A1 (en) 2011-06-09
JP2016119910A (ja) 2016-07-07
EP2507365A1 (en) 2012-10-10
CN102822332A (zh) 2012-12-12
WO2011068896A1 (en) 2011-06-09
JP2019083819A (ja) 2019-06-06
CA2781969A1 (en) 2011-06-09
KR20210120136A (ko) 2021-10-06
JP2013512673A (ja) 2013-04-18
JP2024177183A (ja) 2024-12-19
KR20120112511A (ko) 2012-10-11
US20120282693A1 (en) 2012-11-08
JP7343984B2 (ja) 2023-09-13
RU2012127811A (ru) 2014-01-10
US8822218B2 (en) 2014-09-02
AU2010326027A1 (en) 2012-06-21
CA3095576A1 (en) 2011-06-09
JP2022027790A (ja) 2022-02-14
EP2507365A4 (en) 2014-01-01
JP6013187B2 (ja) 2016-10-25
BR112012014104A2 (pt) 2016-07-05
US20200131475A1 (en) 2020-04-30
KR20250048382A (ko) 2025-04-08

Similar Documents

Publication Publication Date Title
JP7343984B2 (ja) ヒト胚性幹細胞由来血管芽細胞からナチュラルキラー細胞および樹状細胞を生成する方法
AU2020264375B2 (en) Method for developing natural killer cells from stem cells
Havenith et al. Mouse resident microglia: Isolation and characterization of immunoregulatory properties with naive CD4+ and CD8+ T‐cells
JP2019142958A (ja) 間葉系間質細胞及びその関連用途
KR101946785B1 (ko) 영장류 다능성 줄기 세포의 조혈계 세포로의 분화
KR20100120723A (ko) 인간 배아 줄기세포 유래의 조혈세포
WO2003039232A2 (en) Endothelial cell derived hemotopoietic growth factor
US20050221482A1 (en) Methods and compositions for obtaining hematopoietic stem cells derived from embryonic stem cells and uses thereof
WO2012133948A1 (ja) 生体組織から単離できるssea-3陽性の多能性幹細胞を含む他家移植用細胞治療用組成物
WO2025077136A1 (zh) 一种制备自然杀伤细胞的方法
HK40017506A (en) Method for developing natural killer cells from stem cells
Thomson et al. Saritha S. D’Souza, John Maufort, Akhilesh Kumar, Jiuchun Zhang, 2 Kimberley Smuga-Otto, 2

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20120703

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20151201

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170227

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20171221

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20170227

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20171221

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20170727

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20151201

Comment text: Amendment to Specification, etc.

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180424

Patent event code: PE09021S01D

AMND Amendment
PX0701 Decision of registration after re-examination

Patent event date: 20181106

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20180724

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20180322

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20171221

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20170727

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20151201

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20190207

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20190207

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20190208

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20220124

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20220124

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20240123

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20250122

Start annual number: 7

End annual number: 7